+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ravulizumab compared to placebo in adult patients at high risk of delayed graft function DGF following deceased donor kidney transplantation. The study aims to show whether ravulizumab can reduce the severity of DGF, specifically by shortening the time patients need dialysis after transplant. This phase 3, randomized, double-blind trial focuses on patients with dialysis-dependent end-stage kidney disease receiving kidneys from specific donor types. Participants will be randomly assigned to one of two groups one receiving intravenous infusions of ravulizumab, and the other receiving placebo infusions. The treatment is given intravenously, and participants receive either the study drug or placebo throughout the study. The trial compares these groups to assess the impact on DGF. The study is conducted across multiple centers and follows participants through 90 days after transplantation to measure outcomes. Throughout the study, participants will undergo regular assessments to monitor their kidney function and dialysis needs. Researchers will measure the time until participants no longer require dialysis, the number of dialysis sessions needed, the incidence of DGF within 7 days post-transplant, and kidney function as measured by eGFR. Safety and efficacy data are collected during the post-transplant period, with primary outcome measurements taken through 90 days after transplant. The total participation period extends until the studys completion in 2028.

Age: 18Years +All GendersPhase 3
130 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a limited duration treatment combining acalabrutinib and venetoclax in patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have relapsed after initially responding to first-line therapy with covalent BTKi and BCL2i drugs, with or without obinutuzumab. The study focuses on participants who maintained at least a partial remission for two years following their first treatment. Participants will receive a lead-in phase of two cycles of acalabrutinib, followed by either 12 or 22 cycles of the combined acalabrutinib and venetoclax treatment, depending on assigned risk cohort based on disease markers IGHV mutation and TP53 status. The total study duration for each participant is approximately five years, which includes up to four years of follow-up after treatment completion. During the study, participants will undergo regular assessments to measure the overall response rate at multiple time points during treatment cycles and annually thereafter. Additional evaluations include progression-free survival, duration of response, event-free survival, time to next treatment, overall survival, and rates of undetectable minimal residual disease. Safety and tolerability of the second-line treatment will be monitored throughout the five-year period. Participants will have visits and tests according to this schedule to track treatment effects and disease status.

Age: 18Years - 130YearsAll GendersPhase 2
47 locations